

The Inhibition of Glutathione Reductase by Quinones

Daiva A. Bironaitė, Narimantas K. Čėnas,
Juozas J. Kulys

Institute of Biochemistry, Lithuanian Academy of
Sciences, 232600 Vilnius, Lithuania

Alexander G. Medentsev, Vasilij K. Akimenko

Institute of Biochemistry and Physiology of
Microorganisms, USSR Academy of Sciences,
142292 Pushchino, USSR

Z. Naturforsch. **46c**, 966–968 (1991);
received March 4/May 7, 1991

Glutathione Reductase, Inhibition, Quinones

Fully substituted quinones including some naturally occurring oxyquinones acted as inhibitors of yeast glutathione reductase (EC 1.6.4.2). They were competitive, mixed or uncompetitive inhibitors for NADPH, possessing K_i in the range of 1–200 μM and uncompetitive inhibitors for glutathione. Rhein (4,5-dioxy-9,10-anthraquinone-2-carboxylic acid) and 9,10-phenanthrenequinone were the most effective inhibitors. It is concluded that certain quinones can bind to the NADP(H)-binding site and to the heteroaromatic binding site at the interface domain (P. A. Karplus, E. F. Pai, and G. E. Schulz, Eur. J. Biochem. **178**, 693–703 (1989)) of the enzyme.

Introduction

Glutathione reductase (EC 1.6.4.2) contains FAD and redox active disulfide in the active center [1–3] and catalyzes the reversible oxidation of NADPH by GSSG. This enzyme is responsible for the maintenance of sufficiently high concentrations of GSH and is one of the key enzymes in the protection against the “oxidative stress” – an increased concentration of radicals and other activated forms of oxygen [4]. Therefore its inhibitors and inactivators are often used as antitumour, antiparasitic or antimalarial agents [5–7]. It is supposed that heteroaromatic inhibitors of glutathione reductase bind to the interface domain at the site which is distinct from NADP(H) and GSSG binding sites [7, 8].

The data of present communication show that certain quinones, including the naturally occurring ones may act as potent inhibitors of glutathione

reductase. This may be an additional factor of their toxicity apart from their redox cycling and reaction with cellular nucleophiles [9].

Materials and Methods

Yeast glutathione reductase (Sigma) was additionally purified up to $A_{280}/A_{460} = 7.7\text{--}7.9$ [1]. The enzyme concentration was determined using $\epsilon_{460} = 11 \text{ mM}^{-1}\text{cm}^{-1}$. NADPH, NADP⁺ and DTT (Serva), GSSG and GSH (Chemapol, Czechoslovakia), rhein (4,5-dihydroxy-9,10-anthraquinone-2-carboxylic acid, Aldrich), duroquinone (Sigma) were used as received. Alizarin (2,3-dihydroxy-9,10-anthraquinone), 9,10-anthraquinone-2-sulphonate, 1,5-dioxy-9,10-anthraquinone and 9,10-phenanthrenequinone (Reakhim, USSR) were recrystallized from ethanol or benzene. Chrisophanol (2-methyl-4,5-dihydroxy-9,10-anthraquinone) was extracted from the cultural fluid of *Verticillium dahliae*, javanicin (2-methoxymethylene-3-methyl-5,8-dioxy-7-methoxy-1,4-naphthoquinone) – from *Fusarium decemcellulare*, and pigment G-2N (2-methyl-4,7,9,12-tetraoxy-5,6-dihydrobenz[a]-naphthacene-8,13-dione) – from *Frankia* sp. ANP 190107 as described earlier [10, 11]. The structural formulae of some uncommonly used quinones are presented in Fig. 1. The reaction rate was determined using a Hitachi-557 spectrophotometer according to the NADPH absorption change ($\Delta\epsilon_{340} = 6.2 \text{ mM}^{-1}\text{cm}^{-1}$) at 25 °C in 0.1 M K-phosphate-citrate, pH 7.0, containing 1 mM EDTA. The enzymatic GSH-linked reduction of NADP⁺ was done in the presence of 10 mM DTT [12]. TN of the enzyme is a number of NADP(H) consumed by FAD per 1 s.

Results and Discussion

By analogy to previous data [1, 2], the GSSG-linked oxidation of NADPH by glutathione reductase follows a “ping-pong” mechanism. TN_{max} of the enzyme (at saturating concentration of both substrates) at pH 7.0 is 240 s^{-1} .

Since the partially substituted quinones may react with GSH formed during the reaction of glutathione reductase [9], only the fully substituted compounds were tested. It was found that rhein was potent inhibitor of glutathione reductase, acting as the mixed-type inhibitor for NADPH (Fig. 2). The inhibition is not linear according to the in-

Abbreviations: GSSG, oxidized glutathione; GSH, reduced glutathione; DTT, dithiothreitol; TN, turnover number; TN/K_m , bimolecular rate constant.

Reprint requests to N. K. Čėnas.

Verlag der Zeitschrift für Naturforschung, D-7400 Tübingen
0939–5075/91/0900–0966 \$ 01.30/0



Dieses Werk wurde im Jahr 2013 vom Verlag Zeitschrift für Naturforschung in Zusammenarbeit mit der Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. digitalisiert und unter folgender Lizenz veröffentlicht: Creative Commons Namensnennung-Keine Bearbeitung 3.0 Deutschland Lizenz.

Zum 01.01.2015 ist eine Anpassung der Lizenzbedingungen (Entfall der Creative Commons Lizenzbedingung „Keine Bearbeitung“) beabsichtigt, um eine Nachnutzung auch im Rahmen zukünftiger wissenschaftlicher Nutzungsformen zu ermöglichen.

This work has been digitalized and published in 2013 by Verlag Zeitschrift für Naturforschung in cooperation with the Max Planck Society for the Advancement of Science under a Creative Commons Attribution-NoDerivs 3.0 Germany License.

On 01.01.2015 it is planned to change the License Conditions (the removal of the Creative Commons License condition “no derivative works”). This is to allow reuse in the area of future scientific usage.




Fig. 1. Structural formulae of quinones used: chriso-phanol (**Ia**), rhein (**Ib**), javanicin (**II**), G-2 N (**III**).




Fig. 2. The influence of rhein on the forward reaction of glutathione reductase. Concentration of rhein: 0 (1), 2 μM (2), 5 μM (3), 10 μM (4), 20 μM (5), 35 μM (6) and 55 μM (7); concentration of GSSG: 300 μM .

tercepts (reciprocal maximal rates of reaction). The double reciprocal plot of inhibition degree vs. inhibitor concentration [6] gives $K_i = 1.1 \mu\text{M}$ and the maximal degree of inhibition, 93%. The inhibition of rhein is linear according to the slopes (reciprocal TN/K_m of NADPH) giving $K_i = 8 \mu\text{M}$. Javanicin was another mixed-type inhibitor possessing K_i of 70 μM and 100 μM (according to intercepts and slopes). Other quinones were either linear competitive inhibitors (alizarin, $K_i = 20 \mu\text{M}$; chriso-phanol, $K_i = 34 \mu\text{M}$; G-2 N, $K_i = 40 \mu\text{M}$; 1,5-dioxanthraquinone, $K_i = 70 \mu\text{M}$), either uncompetitive inhibitors for NADPH (duroquinone, $K_i = 200 \mu\text{M}$; anthraquinone sulfonate, $K_i = 50 \mu\text{M}$; phenanthrene quinone, $K_i = 1.8 \mu\text{M}$, maximal inhibition degree, 73%). Since phenanthrene quinone was the oxidant of glutathione reductase ($\text{TN}_{\text{max}} = 5 \text{ s}^{-1}$, $\text{TN}/K_m = 10^4 \text{ M}^{-1} \text{ s}^{-1}$) the inhibition patterns were obtained after the subtraction of rates of this reaction. All quinones tested were the uncompetitive inhibitors for GSSG.

The reverse reaction of glutathione reductase – GSH-linked reduction of NADP^+ is characterized by a transition from “ping-pong” to “sequential” mechanism at high concentrations of NADP^+ [12]. This is indicated by the transition of a series of parallel lines to the converging ones in the Lineweaver-Burk plots (Fig. 3). In this case rhein de-




Fig. 3. The influence of rhein on the reverse reaction of glutathione reductase. Concentration of rhein: 0 (1, 2), 20 μM (3, 4); concentration of GSH: 30 mM (1, 3), 10 mM (2, 4). The data in the absence and in the presence of 50 μM of anthraquinone sulfonate are marked by symbols (●) and (□), respectively, on curves 1 and 2.

creases TN/K_m of $NADP^+$ and does not affect TN_{max} , while anthraquinone sulfonate almost does not influence the reaction kinetics.

The data presented indicate that certain quinones (rhein, phenanthrene quinone) are potent inhibitors of glutathione reductase, similar to certain flavin derivatives, used as antimalarial agents [7]. Thus the additional factor of influence of quinones on the system of glutathione metabolism is demonstrated, which may attribute to their toxicity to some extent. This is especially interesting for naturally occurring oxyquinones which activity is associated with the inhibition of mitochondrial electron transport chain (rhein, G-2N) [11, 13] or redox cycling (javanicin) [10]. It seems that quinones being uncompetitive inhibitors for $NADPH$ bind to the interface domain of enzyme which is distinct from $NADP(H)$ and $GSSG$ -binding sites [8]. Such a character of binding is proposed for

flavins and nitrofurans [6, 7], which inhibit glutathione reductase in a similar way. Evidently, oxyquinones being competitive inhibitors for $NADPH$ bind at its binding site in oxidized glutathione reductase. It is known that certain oxyquinones bind to $NAD(P)H$ -binding centers of flavoproteins [13, 14]. The mixed character of inhibition of rhein (Fig. 2) and javanicin may be explained by their binding both at the $NADP(H)$ -binding site and at the interface domain. The binding of rhein to the $NADP(H)$ -binding site is evident from data of Fig. 3. The reasons for different specificity of rhein comparing to other oxyquinones remain unclear. It is possible that 2-carboxyl group of rhein takes a definite part in the complexation, since an analogous 2-methyl-substituted compound, chrisophanol (Fig. 1) inhibits glutathione reductase in a different way.

- [1] V. Massey and C. H. Williams, Jr., *J. Biol. Chem.* **240**, 4470–4480 (1965).
- [2] C. H. Williams, Jr., in: *The Enzymes* 13 (P. D. Boyer, ed.), 3rd Ed., **Vol. 13**, pp. 89–173, Academic Press, New York 1976.
- [3] E. F. Pai and G. E. Schulz, *J. Biol. Chem.* **258**, 1752–1757 (1983).
- [4] R. H. Schirmer, F. Lederbogen, R. L. Krauth-Siegel, G. Eisenbrandt, G. Schulz, and A. Jung, in: *Flavins and Flavoproteins 8* (R. C. Bray, P. C. Engel, and S. G. Mayhew, eds.), pp. 847–859, Walter de Gruyter, Berlin 1984.
- [5] Y. Zhang, E. Hempelmann, and R. H. Schirmer, *Biochem. Pharmacol.* **37**, 855–860 (1988).
- [6] L. Grinblat, C. M. Sreider, and A. O. M. Stoppani, *Biochem. Pharmacol.* **38**, 767–772 (1989).
- [7] K. Becker, R. I. Christopherson, W. B. Cowden, N. H. Hunt, and R. H. Schirmer, *Biochem. Pharmacol.* **39**, 59–65 (1990).
- [8] P. A. Karplus, E. F. Pai, and G. E. Schulz, *Eur. J. Biochem.* **178**, 693–703 (1989).
- [9] T. W. Gant, D. N. R. Rao, R. P. Mason, and G. M. Cohen, *Chem. Biol. Interactions* **65**, 157–173 (1988).
- [10] A. G. Medentsev and V. K. Akimenko, *Biokhimiya* **53**, 289–296 (1988).
- [11] A. G. Medentsev, B. P. Baskunov, O. S. Stupar, M. Y. Nefedova, and V. K. Akimenko, *Biokhimiya* **54**, 926–932 (1989).
- [12] G. A. Rakauskienė, N. K. Čėnas, and J. J. Kulys, *FEBS Lett.* **243**, 33–36 (1989).
- [13] A. Floridi, S. Castiglione, and C. Bianchi, *Biochem. Pharmacol.* **38**, 743–751 (1989).
- [14] P. C. Preusch, *Biochem. Biophys. Res. Commun.* **137**, 781–787 (1986).